On Friday, Viking Therapeutics Inc (NASDAQ: VKTX) opened higher 3.76% from the last session, before settling in for the closing price of $27.40. Price fluctuations for VKTX have ranged from $18.92 to $81.73 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted -86.48% at the time writing. With a float of $108.99 million, this company’s outstanding shares have now reached $112.29 million.
In an organization with 36 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Viking Therapeutics Inc (VKTX) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Viking Therapeutics Inc is 2.96%, while institutional ownership is 69.45%. The most recent insider transaction that took place on Mar 31 ’25, was worth 29,943. In this transaction Director of this company bought 1,240 shares at a rate of $24.15, taking the stock ownership to the 1,240 shares. Before that another transaction happened on Jan 06 ’25, when Company’s President & CEO sold 194,490 for $42.75, making the entire transaction worth $8,313,601. This insider now owns 2,366,570 shares in total.
Viking Therapeutics Inc (VKTX) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.48 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -86.48% per share during the next fiscal year.
Viking Therapeutics Inc (NASDAQ: VKTX) Trading Performance Indicators
Check out the current performance indicators for Viking Therapeutics Inc (VKTX). In the past quarter, the stock posted a quick ratio of 44.25.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.15, a number that is poised to hit -0.45 in the next quarter and is forecasted to reach -2.56 in one year’s time.
Technical Analysis of Viking Therapeutics Inc (VKTX)
Let’s dig in a bit further. During the last 5-days, its volume was 3.25 million. That was inferior than the volume of 4.38 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 44.46%. Additionally, its Average True Range was 1.87.
During the past 100 days, Viking Therapeutics Inc’s (VKTX) raw stochastic average was set at 36.46%, which indicates a significant decrease from 57.95% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 60.42% in the past 14 days, which was lower than the 77.96% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $26.48, while its 200-day Moving Average is $44.94. However, in the short run, Viking Therapeutics Inc’s stock first resistance to watch stands at $29.09. Second resistance stands at $29.76. The third major resistance level sits at $30.37. If the price goes on to break the first support level at $27.81, it is likely to go to the next support level at $27.20. Assuming the price breaks the second support level, the third support level stands at $26.53.
Viking Therapeutics Inc (NASDAQ: VKTX) Key Stats
There are currently 112,310K shares outstanding in the company with a market cap of 3.19 billion. Presently, the company’s annual sales total 0 K according to its annual income of -109,960 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -45,630 K.
